DKSH’s Business Unit Performance Materials, a leading distributor of specialty chemicals and ingredients, will provide business development, marketing, sales, logistics, and distribution services for Southern RNA’s cutting-edge messenger ribonucleic acid (mRNA) raw material and vaccines in India. mRNA is a type of single-stranded RNA involved in protein synthesis. The partnership was unveiled at the recent BioAsia 2024 conference.

Southern RNA is an Australian-based company recognized as an expert in developing and manufacturing pharmaceutical ingredients. The company specializes in producing nucleic acid products that support the clinical development of therapeutic products.

DKSH has been entrusted by Southern RNA to grow their pharmaceutical business in India. This is thanks to DKSH’s extensive distribution network, highly specialized commercial and technical teams, as well as strong capabilities in logistics and value-added services, including technical and regulatory support.

Dr Romain Tropée, Head of Science and Technology, Southern RNA, commented: “We are thrilled to announce our strategic partnership with DKSH, marking a significant step towards Southern RNA’s entry into the Indian pharmaceutical market. This collaboration, unveiled at BioAsia 2024, embodies the immense potential for cooperation between Australia and India in pharmaceutical innovation. Our suite of reagents and services, tailored for RNA-based therapeutics and vaccines, including our flagship mRNA capping reagent, Co Cap® A, aims to empower our clients to pioneer the next wave of medicinal breakthroughs with the highest quality reagents. We eagerly anticipate the advancements this partnership will bring to the forefront of healthcare and medicine.”

Vishal Jawale, Managing Director and Country Management Head, DKSH India, commented: “We are very pleased to sign a distribution agreement with Southern RNA in India. Our deep market insights and broad range of services in the region will enable us to increase growth for Southern RNA’s mRNA raw materials and drug substances as well as generate more value for our wide customer base by using traditional and digital distribution and marketing channels.”